New immune therapy combo targets stubborn lymphoma
NCT ID NCT06723457
Summary
This study is testing whether a combination of two drugs, epcoritamab and lenalidomide, can help control a specific type of aggressive lymphoma that has come back or hasn't responded to other treatments. The trial is for adults whose cancer is linked to a weakened immune system and who are not eligible for certain other advanced therapies. The goal is to see if this drug pair can shrink the cancer and keep it under control for a longer period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT B-CELL NON-HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Northwestern University
Chicago, Illinois, 60611, United States
Conditions
Explore the condition pages connected to this study.